黏膜类天疱疮患者的临床与诊断特征及治疗反应:一项回顾性队列研究
该回顾性队列研究分析了145例黏膜类天疱疮(MMP)患者的临床与诊断特征及治疗反应。结果显示口腔黏膜最常受累(86.9%),初始其他黏膜部位受累的患者中41.7%后续出现眼部病变;抗层粘连蛋白-332抗体阳性患者恶性肿瘤发生率显著高于阴性患者(35.3% vs 10.9%,P=0.007)。77.1%患者接受全身免疫抑制或免疫调节治疗,其余22.9%接受局部治疗,不良事件常见。
要点
- MMP患者中多部位受累占58.6%,口腔黏膜受累最常见(86.9%)。
- 抗层粘连蛋白-332抗体阳性患者恶性肿瘤发生率较阴性者显著升高(35.3% vs 10.9%,P=0.007)。
- 77.1%患者接受全身免疫抑制或免疫调节治疗,不良事件常见。
核心结论
- MMP临床表现异质,病程中可能出现新症状。
- 作者认为MMP患者应考虑癌症筛查,尤其抗层粘连蛋白-332抗体阳性者。
研究设计与样本
- 回顾性队列研究,纳入145例黏膜类天疱疮(MMP)患者,回顾其临床与诊断特征及治疗反应。
主要发现
- 单部位受累占41.4%,多部位受累占58.6%。
- 黏膜受累部位依次为口腔86.9%、眼部30.3%、皮肤26.2%、生殖器黏膜25.5%、鼻黏膜23.4%、咽和/或喉黏膜17.2%。
- 初始其他黏膜部位受累的患者中,41.7%在病程中出现眼部病变。
- 抗层粘连蛋白-332抗体阳性患者恶性肿瘤发生率为35.3%,无该抗体患者为10.9%(P=0.007)。
- 77.1%患者接受全身免疫抑制或免疫调节治疗,多部位受累(P<0.001)、眼部受累(P<0.001)及咽和喉受累(P=0.002)者更常接受该治疗;其余22.9%接受局部治疗;不良事件常见。
关键数值与推荐
- 抗层粘连蛋白-332抗体阳性患者恶性肿瘤发生率为35.3%,无该抗体患者为10.9%(P=0.007)。
- 全身免疫抑制或免疫调节治疗用于77.1%患者,局部治疗用于22.9%患者。
临床怎么用
- 作者认为MMP患者应考虑癌症筛查,尤其抗层粘连蛋白-332抗体阳性者。
局限性
- 回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The variable clinical severity of mucous membrane pemphigoid (MMP) often leads to diagnostic and therapeutic delays. OBJECTIVE: To describe the characteristics of a large cohort of patients with MMP. METHODS: A retrospective review of clinical and diagnostic characteristics as well as treatment responses in 145 patients with MMP. RESULTS: Monosite involvement was seen in 41.4% and multisite involvement in 58.6% of the patients. The oral mucosa was affected in 86.9% of the patients, followed by the ocular mucosa (30.3%), skin (26.2%), genital mucosa (25.5%), nasal mucosa (23.4%), and pharyngeal and/or laryngeal mucosa (17.2%). Ocular disease developed during the disease course in 41.7% of patients with initially other mucosal site involvement. The malignancy rate was significantly higher in patients with autoantibodies against laminin-332 than in patients with MMP without laminin-332 autoantibodies (35.3% vs 10.9%, respectively; P = .007). Systemic immunosuppressive or immunomodulatory therapy was administered to 77.1% of the patients, mainly to patients with multisite (P < .001), ocular (P < .001), and pharyngeal and laryngeal involvement (P = .002). The remaining patients (22.9%) received topical therapy. Adverse events were frequently reported. LIMITATIONS: Retrospective design. CONCLUSION: Patients with MMP present with a heterogeneous clinical presentation, and new symptoms may develop during the disease course. Cancer screening should be considered for patients with MMP and, in particular, for those with autoantibodies against laminin-332.
引用
- Rashid H, Meijer JM, Bolling MC, et al. Insights into clinical and diagnostic findings as well as treatment responses in patients with mucous membrane pemphigoid: A retrospective cohort study. J Am Acad Dermatol. 2021. PMID: 34896128. doi:10.1016/j.jaad.2021.11.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。